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Sleep disorders (SDs) are one of the most frequent non-motor symptoms of Parkinson’s 
disease (PD), usually increasing in frequency over the course of the disease and dis-
ability progression. SDs include nocturnal and diurnal manifestations such as insomnia, 
REM sleep behavior disorder, and excessive daytime sleepiness. The causes of SDs in 
PD are numerous, including the neurodegeneration process itself, which can disrupt 
the networks regulating the sleep–wake cycle and deplete a large number of cerebral 
amines possibly playing a role in the initiation and maintenance of sleep. Despite the 
significant prevalence of SDs in PD patients, few clinical trials on SDs treatment have 
been conducted. Our aim is to critically review the principal therapeutic options for the 
most common SDs in PD. The appropriate diagnosis and treatment of SDs in PD can 
lead to the consolidation of nocturnal sleep, the enhancement of daytime alertness, and 
the amelioration of the quality of life of the patients.
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iNTRODUCTiON
Non-motor symptoms (NMSs) are present in almost all patients with Parkinson’s disease (PD) fre-
quently preceding the onset of motor symptoms (1). NMSs usually impact on the patients’ quality 
of life, representing a possible cause of institutionalization (2, 3). Among NMSs, after psychiatric 
symptoms, sleep disorders (SDs) constitute the second most frequent complaint, affecting 64% of 
PD patients, ranging from 41.1% in naïve patients to 78.3% in complicated patients (1). SDs in PD 
are multifactorial and include nocturnal and diurnal manifestations. Reduced sleep efficiency and 
an increased number of awakenings characterize sleep in PD (4). These disturbances are linked, 
on one side, to PD motor (akinesia, rigidity, and dystonia) and autonomic symptoms (nocturia) 
and, on the other side, to the presence of concomitant SDs such as REM sleep behavior disorder 
(RBD), restless legs syndrome (RLS), or breathing disorders such as obstructive sleep apnea (OSA) 
(5). Diurnal manifestations include excessive daytime sleepiness (EDS) and sudden sleep attacks, 
which could be a consequence of nocturnal sleep impairment or dopaminergic treatment or, more 
interestingly, to the neurodegenerative process of PD itself dysregulating the circadian sleep–wake 
rhythm (4–8). Apart from instrumental tools, specific and validated scales have been designed to 
evaluate SDs in PD [Parkinson’s Disease Sleep Scale (PDSS) and its modified version (PDSS-2), 
the Scales for Outcomes in PD-Sleep (SCOPA-S)] (9, 10). Despite the importance of identifying 
and treating SDs in PD patients, large-scale, randomized controlled trials for treatment options in 
Table 1 | Diagnostic criteria for chronic insomnia (international 
Classification of Sleep Disorders).
Criteria A–F must be met:
 A. The patient reports, or the patient’s parent or caregiver observes, one or 
more of the following:
 1. Difficulty initiating sleep.
 2. Difficulty maintaining sleep.
 3. Waking up earlier than desired.
 4. Resistance to going to bed on appropriate schedule.
 5. Difficulty sleeping without parent or caregiver intervention.
 B. The patient reports, or the patient’s parent or caregiver observes, one or 
more of the following related to the nighttime sleep difficulty:
 1. Fatigue/malaise.
 2. Attention, concentration, or memory impairment.
 3. Impaired social, family, occupational, or academic performance.
 4. Mood disturbance/irritability.
 5. Daytime sleepiness.
 6. Behavioral problems (e.g., hyperactivity, impulsivity, and aggression).
 7. Reduced motivation/energy/initiative.
 8. Proneness for errors/accidents.
 9. Concerns about or dissatisfaction with sleep.
 C. The reported sleep/wake complaints cannot be explained purely by 
inadequate opportunity (i.e., enough time is allotted for sleep) or inadequate 
circumstances (i.e., the environment is safe, dark, quiet, and comfortable) 
for sleep.
 D. The sleep disturbance and associated daytime symptoms occur at least 
three times per week.
 E. The sleep disturbance and associated daytime symptoms have been 
present for at least three months.
 F. The sleep/wake difficulty is not better explained by another sleep disorder.
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this population are lacking. Our narrative review will discuss the 
available optimal therapeutic strategies, based on the literature 
data, to use in clinical practice.
NOCTURNal SDs
insomnia
According to the International Classification of SDs, chronic 
insomnia is characterized by difficulties initiating sleep, main-
taining sleep or waking up earlier than desired in the morning 
(Table 1) (11). Insomnia is the most frequent SD in PD patients 
(36.9%) with a prevalence ranging from 27 to 80%. The most 
frequent complaint of PD patients is maintenance insomnia with 
frequent awakenings and sleep fragmentation (81%), but initial 
(18%) and terminal insomnia (40%) are also possible (12). Video-
polysomnographic studies showed an increased sleep latency and 
frequent and sometimes prolonged intra-sleep awakenings. The 
representation of the different sleep stages is physiological (4, 13). 
In addition to the neurodegeneration process of PD, the most 
important factors for developing insomnia are female gender, 
PD duration, and the presence of depression and anxiety. Other 
factors, such as cough, cold sensations, heat sensations, and pain, 
which are more common in PD compared to controls, are sug-
gested as contributing factors for sleep fragmentation. Moreover, 
some drugs such as dopamine agonists and their withdrawal, 
entacapone, selegiline, and rasagiline (although literature data 
are conflicting) could increase the risk of insomnia if compared 
to placebo (14–19).
Instead, akinesia, bed-turning difficulties, cramps, nocturia, 
difficult breathing, and nightmares seem not to be direct causes 
of insomnia in PD (5, 13, 20).
The treatment for insomnia (pharmacological or behavioral) 
must be preceded by a correct identification of the type of insom-
nia (initial, of maintenance, or terminal) and of possible disorders 
and factors causing it (Figure 1). It is necessary to rule out and 
treat motor or sleep breathing disorders, if present. If insomnia 
is iatrogenic or due to motor complications of PD, it is useful 
to modify the therapy. Levodopa–carbidopa controlled-release 
(LD-CR) improves sleep-associated motor symptoms that may 
contribute to insomnia, although data documenting an objective 
improvement in sleep parameters or in sleep satisfaction are insuf-
ficient. A double-blind crossover study, comparing the effect of a 
single dose of 100/25 mg LD-CR with placebo, in 40 fluctuating 
PD patients, showed an improvement in nocturnal akinesia and 
only a not-significant trend of increase in total sleep time without 
any improvement in sleep latency and sleep fragmentation (21). 
In another randomized study on 32 akinetic rigid PD patients, 
LD-CR 200 mg before sleeping reduced nocturnal akinesia but 
did not significantly improve any objective sleep parameter, 
such as sleep latency, total sleep time, and number of arousals, 
compared to placebo (22).
The effect of dopamine agonists (DAs) on SDs in PD has 
been evaluated usually as secondary endpoint in many ran-
domized controlled trials showing an improvement in sleep 
parameters. Ropinirole 24-h prolonged release (2–24 mg/day) 
as adjunctive therapy to levodopa, significantly improved PDSS 
scores in 93/198 patients with motor fluctuations enrolled in 
a randomized, placebo-controlled study (23). A double-blind, 
double-dummy, randomized, placebo-controlled trial, compar-
ing the efficacy of pramipexole (up to 4.5 mg/day) and trans-
dermal rotigotine patch (up to 16 mg/day) on advanced-stage 
PD patients treated with LD showed for both drugs small, but 
significant, improvement in sleep parameters assessed by PDSS 
(24). Rotigotine transdermal patch (2–16  mg/day) improved 
early morning motor function and PDSS-2 scores in a multi-
national, randomized double-blind placebo-controlled study 
on 287 PD patients with unsatisfactory early morning motor 
symptom control and motor symptoms during the night (25). 
These data have been confirmed by two successive actigraphic 
and polysomnographic studies specifically designed to objec-
tively evaluate the effect of rotigotine on sleep. These studies 
demonstrated that the rotigotine patch reduces nocturnal 
motor activity, duration of wake after sleep onset (WASO), 
nocturia, pain, and coexisting SDs such as RLS in PD patients. 
The rotigotine patch also reduces the number and the duration 
of daytime sleep episodes and improves quality of life (Figure 2) 
(26, 27). Finally, rasagiline, a monoamine oxidase B inhibitor, 
can improve insomnia probably increasing endogenous mela-
tonin levels. A single-center, prospective, observational study 
compared 19 PD patients treated with LD 200–300  mg/day 
associated with rasagiline 1 mg/day with 19 PD patients treated 
only with LD 200–300  mg/day. After 12  weeks of treatment, 
the group treated with LD and rasagiline showed a significant 
reduction in mean sleep latency and an increase in mean total 
sleep time (28).
FigURe 1 | Treatment algorithm for insomnia.
3
Loddo et al. Sleep Disorders Treatment in PD
Frontiers in Neurology | www.frontiersin.org February 2017 | Volume 8 | Article 42
If insomnia is not iatrogenic and not due to PD motor com-
plications, the principal therapy remains the cognitive behavioral 
therapy (29, 30). This treatment comprises advice on sleep–wake 
behavior hygiene, stimulus control, sleep restriction, relaxation, 
and cognitive techniques (20).
In the cases in which pharmacological therapy is necessary, 
eszopiclone, doxepin, zolpidem, trazodone, ramelteon, and mela-
tonin could be useful although these drugs are investigational for 
the treatment of insomnia in PD because there is insufficient 
evidence regarding their efficacy. To avoid tolerance, hypnotic 
drugs should ideally be used for no longer than 4–5  weeks 
(30). Eszopiclone (2–3  mg/day) was tested in 30 PD patients 
with insomnia in a placebo-controlled trial. This drug does not 
increase total sleep time but reduces awakenings during the 
night and improves sleep quality. Thirteen percent of patients 
reported mild adverse events such as dizziness and sedation (31). 
In a three-arm 6-week placebo randomized pilot study in 18 PD 
patients, treated respectively with doxepin (10  mg daily) and 
cognitive behavioral therapy, doxepin improved the Pittsburgh 
Sleep Quality Index-Sleep Disturbances Subscale, the SCOPA-
night score, the Insomnia Severity Index, the Fatigue Severity 
Scale, and the Montreal Cognitive Assessment. Adverse events, 
such as mild fatigue, transient mild nausea and unsteadiness 
were reported in only three cases (32). The use of zolpidem for 
insomnia in PD patients is still debated because randomized 
controlled trials in this population are lacking. Drowsiness and 
risk of falls are potential relevant side effects in PD (33, 34). 
Also, trazodone, one of the most used drugs for insomnia in 
elderly people with a safety profile could present possible side 
effects such as increased rates of falls, dizziness, impairments in 
short-term memory, and worsening in verbal memory (35–39). 
Ramelteon has been studied in PD patients with RBD improving 
sleep latency (40). Melatonin is established as effective in improv-
ing patients’ perception of sleep quality, but data are conflicting 
regarding objective improvement in sleep polysomnographic 
parameters (41, 42). A multi-site double-blind placebo-controlled 
crossover trial in 40 PD patients showed that melatonin 50 mg 
compared to placebo improved total sleep time, while melatonin 
5 mg improved the subjective sleep disturbances perception and 
reduced daytime sleepiness (43). Another trial in 16 PD patients 
showed that melatonin 3 mg improved the subjective quality of 
sleep (44). Globally considering the circadian sleep–wake cycle 
dysregulation affecting PD patients, melatonin is effective with a 
good safety profile (8, 45).
Summing up, the treatment of insomnia in PD needs to rule 
out and eventually to treat other sleep-related motor and breath-
ing disorders. The second step is to treat PD motor complications, 
if present, using prolonged release dopaminergic drugs or LD. 
FigURe 2 | actigraphic recordings of a patient with Parkinson’s disease with sleep complaints in basal condition (T0) and during therapy with 
rotigotine 24-h transdermal patch (T1). During rotigotine therapy (T1), the actigraphic recording demonstrates a marked reduction in nighttime motor activity 
(gray stripe) compared to the basal period. A daytime reduction in diurnal naps is also noticeable (see period between 9 and 11 a.m.).
4
Loddo et al. Sleep Disorders Treatment in PD
Frontiers in Neurology | www.frontiersin.org February 2017 | Volume 8 | Article 42
In all the cases, it is mandatory to recommend sleep hygiene 
rules and cognitive-behavioral therapy, alone or in association 
with melatonine also at high dosages. If these measures are inef-
fective, a pharmacological therapy with Zolpidem, Eszopiclone, 
Trazodone, or Doxepine could be added (Figure 1).
Nocturia
Nocturia affects 35% of PD patients (1). The mechanism underly-
ing nocturia remains unclear, but it has been suggested that it 
may be related to autonomic modifications and to the loss of the 
normal D1-mediated inhibition of micturition associated with 
detrusor hyperreflexia (46–50).
Before starting treatment, it is necessary to rule out and treat 
all the secondary causes of nocturia, if present (such as OSAS, 
urinary infections, benign prostatic hypertrophy, heart failure, 
and anxiety) and optimize dopaminergic therapy (51) (Figure 3).
In addition, it is necessary to apply some behavioral rules such 
as reducing water intake late in the afternoon and avoid diuretic 
therapy before sleeping (for more details, see Figure 3). If these 
measures are ineffective, a pharmacological treatment could be 
started also if randomized controlled trials on the drug treatment 
of nocturia in PD patients are lacking. It is uncertain whether 
LD can improve micturition disorders. In a study on 26 LD-naïve 
PD patients, an acute challenge of LD worsened the detrusor’s 
overactivity while, after 2 months of chronic LD therapy, an acute 
challenge showed contrary results (52). Some reports have shown 
storage-facilitating effects of dopaminergic drugs, but there are 
no conclusive data regarding these drugs (50). Subcutaneous 
apomorphine (3–8  mg) reduced detrusor hyperreflexia in 12 
PD patients without dopaminergic therapy (53). Rasagiline 
1 mg incremented bladder capacity and significantly decreased 
residual volume in 20 mild PD patients treated with DAs (54). 
The efficacy of intranasal desmopressin and botulinum toxin 
injections into the detrusor muscle are not sufficiently proven 
as well as the anthicholinergic drugs, which are the most used 
drugs for overactive bladder in elderly people. These drugs need 
caution in PD patients for their side effects such as sleepiness, 
confusion, and cognitive impairment. Among anthicholinergic 
Table 2 | Diagnostic criteria for restless legs syndrome (RlS) 
(international Classification of Sleep Disorders).
Criteria A–F must be met:
 A. An urge to move the legs, usually accompanied by or thought to be caused 
by uncomfortable and unpleasant sensations in the legs. These symptoms 
must:
 1. Begin or worsen during periods of rest or inactivity such as lying down 
or sitting;
 2. Be partially or totally relieved by movement, such as walking or 
stretching, at least as long as the activity continues; and
 3. Occur exclusively or predominantly in the evening or night rather than 
during the day.
 B. The above features are not solely accounted for as symptoms of 
another medical or a behavioral condition (e.g., leg cramps, positional 
discomfort, myalgia, venous stasis, leg edema, arthritis, and habitual foot 
tapping).
 C. The symptoms of RLS cause concern, distress, sleep disturbance, 
or impairment in mental, physical, social, occupational, educational, 
behavioral, or other important areas of functioning.
FigURe 3 | Treatment algorithm for nocturia.
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drugs, M3 receptor selective agents such as solifenacin (5–10 mg/
day), darifenacin (7.5 mg/day), and tolterodine (2 mg/day) have 
a better tolerability than non-selective drugs such as oxybutinin 
(5 mg/bid) and trospium chloride (10–20 mg/bid) (50).
Sleep-Related Movement Disorders
Restless Legs Syndrome
Restless legs syndrome is a sensorimotor disorder occurring in 
the evening or at night, characterized by an urge to move the legs 
usually associated with uncomfortable and unpleasant sensations 
in the legs relieved by movement (Table 2) (11). RLS affects 15% 
of patients with PD and occurs either before or after the onset of 
PD (1). In the de novo untreated populations, the prevalence of 
RLS seems to be similar to that of controls across populations. On 
the contrary, RLS prevalence increases during the course of PD 
and treatment duration, independent of the drug dosages (55). 
PD patients with RLS have higher age at PD onset, worse sleep 
quality, and more cardiovascular and anxiety disturbances (56, 
57). Also, the presence of a secondary condition, such as iron 
deficiency, could explain the association between RLS and PD. 
The pathophysiology of RLS in PD patients is still debated but dif-
fers from that of idiopathic RLS (12). PD patients with RLS could 
have more preserved nigrostriatal dopaminergic pathways than 
those without RLS suggesting a non-linear relationship between 
dopaminergic dysfunction and RLS (57–60).
The RLS diagnosis is clinically based on the presence of the five 
international diagnostic criteria (61, 62). The Hening Telephone 
Diagnostic Interview (HTDI), the Cambridge–Hopkins diagnos-
tic questionnaire for RLS (CH-RLSq), and the RLS diagnostic 
index (RLS-DI) are useful diagnostic instruments, although not 
specific for PD patients (61).
If RLS is mild, it can be managed by only lifestyle changes. 
Therefore, before initiating any pharmacological treatment, it is 
necessary to evaluate the frequency and duration of symptoms 
and their impact on the patient’s quality of life. Chronic renal 
failure, iron, vitamin B12 and folic acid deficiency, serum glucose, 
and HbA1C need to be investigated in order to exclude secondary 
forms. The serum ferritin level should be measured, and, if the 
concentration is <50–75 μg/mL, or if transferrin saturation is less 
than 20%, supplementation with oral iron is recommended. If 
oral iron is poorly tolerated or contraindicated, the intravenous 
administration can also be considered (63). The withdrawal of 
drugs that potentially exacerbate RLS such as antidopaminergic 
Table 3 | Diagnostic criteria for NReM parasomnias (international 
Classification of Sleep Disorders).
Criteria A–E must be met:
A. Recurrent episodes of incomplete awakening from sleep.
B.  Inappropriate or absent responsiveness to efforts of others to intervene or 
redirect the person during the episode.
C.  Limited (e.g., a single visual scene) or no associated cognition or dream 
imagery.
D. Partial or complete amnesia for the episode.
E.  The disturbance is not better explained by another sleep disorder, mental 
disorder, medical condition, medication, or substance use.
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drugs, antihistamines, and antidepressants (except for bupro-
pion) is also recommended (63).
Treatment of RLS in PD patients has not been evaluated in 
controlled studies. DAs have proven effective for RLS. The low-
est possible cumulative daily dose is recommended to prevent 
augmentation, which is a side effect characterized by an overall 
increase in RLS symptoms severity during therapy (63, 64). To 
prevent such augmentation, long-acting DAs should be preferred 
to short acting ones. Alternatively, α2δ ligands (pregabalin 
150–450 mg/day; gabapentin 900–2.400 mg/day; enacarbil 600–
1.800 mg/day) are useful. Dizziness, somnolence, and fatigue are 
common α2δ ligands side effects. In resistant cases, low doses 
of opioids such as long-acting oxycodone or methadone should 
be considered, except for patients with high risk of addiction or 
with preexisting severe constipation, sleep apnea syndrome, or 
prolonged QTc (63). Finally, patients may obtain temporally relief 
by rubbing or massaging the affected limbs, bathing in hot or cold 
water, physical activity, or distracting themselves with mental 
exercises (for example, reading an interesting book at the onset 
of the symptoms) (65).
Periodic Limb Movements (PLMs)
Periodic limb movements are stereotyped and repetitive move-
ments affecting the limbs, in particular, the legs, which can cause 
non-restorative sleep (11). More than 15 movements per hour 
of sleep are considered pathological, although the prevalence of 
PLMs increases with age also in the normal population. In elderly, 
the prevalence of PLMs is estimated between 25 and 58% (11, 66).
Subjects with PLMs may or may not be aware of the move-
ments that are instead reported by the bed partner. Some authors 
reported a possible link between the presence of PLMs and 
frequent awakenings, daytime sleepiness, fatigue or, more rarely, 
EDS (67–69). PLMs are often associated with RLS, narcolepsy, or 
sleep apnea (70). Eighty percent or more of all RLS patients have 
PLMs (71–73).
It is not clear, if prevalence of PLMs in PD is higher than in 
the general population (74–77). Age, secondary causes such as 
hyposideremia and the loss of dopaminergic cells may explain 
the link existing between PLMs and PD (78, 79). Antidepressants, 
neuroleptics, and lithium could be other potential inducing fac-
tors (11).
Before starting a specific therapy for PLMs, it is important 
to evaluate their clinical impact because PLMs could be only 
an incidental videopolysomnography (VPSG) finding that does 
not disturb sleep. There are few studies directly assessing the 
therapy for PLMs in PD and the principal information regarding 
PLMs treatment comes from RLS patients (63) In RLS patients, 
randomized placebo-controlled studies have established the 
efficacy of DAs for both improvement of RLS symptoms and 
reduction in PLMs. In a cross-sectional study on 19 untreated 




NREM parasomnias are undesired events characterized by an 
incomplete arousal from NREM sleep and include confusional 
arousals, sleepwalking, and sleep terrors (Table  3) (11). The 
prevalence of NREM parasomnias in PD is not clear. A ques-
tionnaire study on 661 PD patients showed that sleepwalking 
had a prevalence of 1.8% while night terrors 3.9% (81). In PD 
patients with RBD, the prevalence of NREM parasomnias (para-
somnia overlap disorder) is higher, reaching respectively, 4.3 
and 8.7% (81). Somnambulism in PD is associated with higher 
incidence of depression and advanced PD stage (82). Probably, 
the neurodegenerative changes of advanced PD influence not 
only the control of muscle tone but also the mechanisms of state 
transition (83).
The first approach to a patient with NREM parasomnias, 
independently of its causes, is to secure the bedroom in which 
the patient sleeps, closing and locking doors or windows, block-
ing stairways, and removing all potentially dangerous objects. 
It is also important to reduce all the possible precipitating and 
predisposing factors such as alcohol consumption, stress, fever, 
sleep deprivation, sleeping in unfamiliar or noise-exposed 
bedrooms. If present, it is necessary to treat OSA and reduce 
or withdraw psychotropic drugs such as phenothiazines, 
anticholinergic agents, and sedative/hypnotic agents (11). 
Clonazepam (CNZ) (0.25–2  mg at bedtime) is the first line 
pharmacologic treatment for NREM parasomnias in adults, 
but its efficacy has not been proved in randomized controlled 
trials (84–87). CNZ was effective in 90% of a series of 20 
patients with parasomnia overlap disorder (88), but there are no 
studies in PD patients. Only four sleepwalkers were identified 
in a set of 165 PD patients. After a 2-year follow-up, two 
patients have had a spontaneous remission of sleepwalking, one 
patient responded to topiramate treatment (100 mg/day) and 
one patient showed a resolution of the episodes after clozapine 
treatment (25/mg die) (89).
REM Parasomnias
Nightmares
Nightmares are vivid and unpleasant dreams recurring in REM 
sleep and causing awakening (Table  4) (11). Their prevalence 
in PD patients seems to be 17.2%, but these data are only based 
on questionnaires (81). Dream contents in PD patients seem 
to be different from controls in particular regarding violence, 
misfortune, and presence of animals. Some authors explain these 
contents in relation to the cognitive and frontal impairment of 
PD patients instead of therapy, mood disorders, hallucinations, 
Table 5 | Diagnostic criteria for ReM sleep behavior disorder 
(international Classification of Sleep Disorders).
Criteria A–D must be met:
 A. Repeated episodes of sleep-related vocalization and/or complex motor 
behaviors.
 B. These behaviors are documented by polysomnography to occur during 
REM sleep or, based on clinical history of dream enactment, are presumed 
to occur during REM sleep.
 C. Polysomnographic recording demonstrates REM sleep without atonia.
 D. The disturbance is not better explained by another sleep disorder, mental 
disorder, medication, or substance use.
Table 4 | Diagnostic criteria for nightmares (international Classification 
of Sleep Disorders).
Criteria A–C must be met:
 A. Repeated occurrences of extended, extremely dysphoric, and well-
remembered dreams that usually involve threats to survival, security, or 
physical integrity.
 B. On awakening from the dysphoric dreams, the person rapidly becomes 
oriented and alert.
 C. The dream experience, or the sleep disturbance produced by awakening 
from it, causes clinically significant distress or impairment in social, 
occupational, or other important areas of functioning as indicated by the 
report of at least one of the following:
 1. Mood disturbance (e.g., persistence of nightmare affect, anxiety, and 
dysphoria).
 2. Sleep resistance (e.g., bedtime anxiety, fear of sleep/subsequent 
nightmares).
 3. Cognitive impairments (e.g., intrusive nightmare imagery, impaired 
concentration, or memory).
 4. Negative impact on caregiver or family functioning (e.g., nighttime 
disruption).
 5. Behavioral problems (e.g., bedtime avoidance, fear of the dark).
 6. Daytime sleepiness.
 7. Fatigue or low energy.
 8. Impaired occupational or educational function.
 9. Impaired interpersonal/social function.
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and the presence of RBD (90). Traumatic events, stress, use of 
antidepressants, alpha-agonists, beta-blockers, and cholinergic 
antagonists are all predisposing and precipitating factors for 
nightmares (91).
The first-line treatment for nightmares is cognitive behavio-
ral therapy, in particular, the imagery rehearsal therapy (IRT), 
but these techniques have not been systematically tested in PD 
patients and need to be confirmed. A placebo-controlled study 
showed that prazosin (9.5 mg/at bedtime) reduced nightmares in 
10 Vietnam veterans. Other studies proved prazosin efficacy, but 
its real effectiveness needs to be tested in larger placebo-controlled 
trials (92–95). Side effects such as orthostatic hypotension could 
discourage its use in PD patients.
REM Sleep Behavior Disorder
REM sleep behavior disorder is a REM parasomnia characterized 
by complex, sometimes violent, and dangerous motor behaviors 
during which the patient acts out the content of his/her dream 
(Table 5) (11). RBD is present in 30% of patients with PD and 
often precedes the onset of motor symptoms (1). The association 
between PD and RBD may be explained considering the brain-
stem abnormalities in regions that control REM sleep such as the 
peduncle pontine nucleus and the laterodorsal tegmental nuclei, 
which are affected during Braak’s stages 1 and 2 (96). Independent 
of pharmacological therapy, in order to guarantee the patient 
and bed partner’s safety, securing the bedroom is necessary 
(Figure 4) (97). It is also necessary to withdraw or reduce drugs 
potentially causing RBD, such as monoamine oxidase inhibitors, 
antidepressants, beta blockers (bisoprolol), opioids (tramadol), 
and centrally acting alpha-agonist hypotensive agents (cloni-
dine) (98–108). If RBD causes sleep disruption or if it influences 
the patient and bed partner’s safety, pharmacological treatment 
is indicated (97). CNZ, 0.25–2 mg 30 min prior to bedtime has 
been a first-line therapy for RBD (97). Several large case series 
proved the efficacy of CNZ in 87–90% RBD patients with or 
without PD, also if no randomized placebo-controlled studies 
have been performed (85, 109–111). Sedation and increased risk 
of fallings are CNZ possible side effects. CNZ is contraindicated 
in moderate and severe OSAS (85, 110, 112). The mechanism of 
action of CNZ is unknown. Considering that it does not suppress 
REM sleep and it does not influence REM muscle tone, probably 
it could modify dream contents or inhibit brainstem locomotor 
pattern generators (113, 114). Recent studies proved that CNZ 
moderately increases total sleep time, sleep efficiency, NREM 
sleep stages (except stage 1), and decreases wake after sleep onset 
(WASO) (115). In PD patients in which CNZ is contraindicated 
(for example, patient with OSAS, cognitive impairment, and 
a high baseline risk of falling), melatonin (3–12  mg, before 
sleeping) could be the treatment of choice. CNZ and melatonin 
appear comparably effective for RBD symptoms and injury 
prevention. Melatonin’s favorable safety and tolerability profile is 
very useful for patients receiving polytherapy and for neurologi-
cally impaired RBD patients who are more sensitive to adverse 
drugs effects (116, 117). A recent meta-analysis of randomized 
clinical trials suggested that exogenous melatonin, improving 
sleep quality in patients with neurodegenerative disorders can 
be considered as a possible mono or add-on therapy in patients 
with RBD (118).
Melatonin mechanisms of action are still not completely 
known, but its use seems to reduce RBD and decrease muscle 
tone during REM sleep. Side effects (morning headache, morn-
ing sleepiness, and delusions/hallucinations) are usually related 
to high doses (117, 119, 120). Pramipexole (0.2–1  mg/night), 
paroxetine (10–40 mg), donepezil (10–15 mg), and rivastigmine 
(4.5–6  mg) may be effective in some refractory cases, but the 
evidence of their efficacy is inconclusive due to the lack of 
randomized controlled trials (97, 121–123). Two studies have 
been carried out on rivastigmine. Rivastigmine compared to 
placebo induced a reduction in the frequency of RBD episodes 
in a pilot placebo-controlled crossover trial on 25 patients with 
mild cognitive impairment (but without PD). Similar results 
have been found in a double-blind, crossover trial in 12 patients 
with PD and RBD resistant to CNZ and melatonin (124, 125). 
Very limited evidence has been reported for zopiclone, benzo-
diazepines other than CNZ, yi-gan san, desipramine, clozapine, 
carbamazepine, and sodium oxybate (97). Ramelteon was effec-
tive in RBD in PD patients in two recent open trials, conducted, 
respectively, in 24 and 12 PD patients, but these promising 
FigURe 4 | Treatment algorithm for ReM sleep behavior disorder.
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results could be confirmed in larger population and for longer 
follow-up. Daytime sleepiness, nausea, delirium, giddiness, and 




Obstructive sleep apnea is characterized by snoring and repeti-
tive episodes of complete (apnea) or partial (hypopnea) upper 
airway obstruction occurring during sleep. The patient typically 
complains of lack of breath, gasping or choking, insomnia, 
non-restorative sleep, and EDS (11). The prevalence of OSA in 
PD is highly controversial, widely ranging from 20 to 60% (5, 
7, 127–129). Although middle-elderly age, fluctuating respira-
tory muscle coordination, autonomic dysfunction, and reduced 
respiratory drive may justify a higher prevalence of OSA in PD 
patients, recent studies demonstrated that OSA’s prevalence in PD 
is the same of the general population. At the same time, sleep 
fragmentation and intermittent hypoxemia due to OSA may 
contribute to and worsen PD (4, 130–136).
The gold standard therapy for OSA is the continuous positive 
airway pressure (CPAP), which normalizes nocturnal respira-
tion improving nighttime oxygenation, sleep architecture (par-
ticularly deepening sleep), and daytime sleepiness (136). The 
control of body weight and sleeping on one’s side during the night 
could be useful. In this case, to relieve the difficulties of turning 
around, adapted physiotherapy and increased dopaminergic 
treatment at night by extra nocturnal doses or sustained release 
drugs may improve OSA (137). Recently, mandibular advance-
ment devices have been shown to be similarly beneficial to 
CPAP in improving OSA (138). There are contradictory reports 
on the modulation of respiratory function by antiparkinsonian 
treatment and the real effect of DAs remains unknown (139, 
140). DAs seem to enhance the risk of central SDs of breath-
ing (141). On the contrary, bedtime long-acting LD seems to 
improve OSA in PD patients as shown in a polygraphic study in 




Excessive daytime sleepiness, first described as “sleep attack” 
characterized by sudden and irresistible overwhelming sleepiness 
without awareness of falling asleep (143), is more often reported 
as sleepiness with prodromes such as tearing or yawning (144, 
145) (Table 6). EDS is present in 21% of patients with PD and 
increases with disease progression (1). Age, sleep–wake cycle 
alteration related to PD, PLM, daytime immobility, and dopa-
minergic medications may contribute to EDS (4, 8, 146–148). 
Moreover, a study on 10,053 drug-naive patients with early 
PD proved that patients who developed EDS after 5  years of 
therapy were those with higher sleepiness at the baseline (149). 
The Multiple Sleep Latency Test (MSLT), the Maintenance of 
Table 6 | Diagnostic criteria for excessive daytime sleepiness 
(international Classification of Sleep Disorders).
Criteria A–D must be met:
 A. The patient has daily periods of irrepressible need to sleep or daytime 
lapses into sleep occurring for at least 3 months.
 B. The daytime sleepiness occurs as a consequence of a significant 
underlying medical or neurological condition.
 C. If an MSLT is performed, the mean sleep latency is ≤8 min and fewer than 
two sleep onset REM periods are observed.
 D. The symptoms are not better explained by another untreated sleep 
disorder, a mental disorder, or the effects of medications or drugs.
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Wakefulness Test (MWT), and the Epworth Sleeping Scale (ESS) 
may be inadequate to detect sleepiness in PD patients (4, 5, 8, 
146, 147, 150). The Inappropriate Sleep Composite Score (ISCS) 
instead has a higher specificity of predicting PD patients with 
increased risk of accidents with motor vehicle due to fall asleep 
while driving (151).
Treatment of EDS in PD is a challenge. First of all, it is neces-
sary to identify and treat any possible SDs that could disrupt 
nocturnal sleep and to withdraw or reduce any possible drugs 
causing hypersomnia such as antidepressants, antipsychotics, 
or sedatives. At the same time, it is important to educate patients 
to apply the sleep hygiene rules (Figure 5). All DAs cause more 
EDS than LD without differences between drugs but with a 
direct relationship with drug dose (152, 153). Combination 
therapy with LD and DAs shows the highest risk of EDS 
(154). Instead, selegeline, amantadine, and entacapone had no 
influence on EDS (155, 156). The association between orally 
dispersible selegiline and DAs may reduce or resolve EDS (150, 
153, 154, 156). If the above strategies do not improve EDS, the 
use of stimulating drugs such as modafinil (100–400 mg/day) 
should be a solution. It seems to improve patients’ perception 
of wakefulness without any objective confirmation (41). Two 
randomized, double-blind, crossover, placebo-controlled trials 
on small groups of PD patients with EDS showed that modafinil 
100–200 mg/day after 2 weeks of treatment, improved the ESS 
scores but not sleep latency on the MWT (157). On the other 
hand, a double-blind, placebo-controlled parallel design trial 
on 40 PD patients treated with modafinil 200–400 mg/day for 
4 weeks showed no improvement of ESS scores (158). A recent 
review and meta-analysis of pharmacological interventions for 
EDS in Parkinson’s disease concluded that modafinil improves 
daytime sleepiness of PD patients also if the significance of 
this improvement was not robust to all sensitivity analyses 
(42). Possible adverse events related to modafinil therapy 
are headache, dry mouth, dizziness, nausea, nervousness, 
insomnia, and generalized itching (42, 159, 160). These side 
effects seem to be mild and decrease with dose reduction (161). 
Nocturnally administered sodium oxybate 3–9 g/night in two 
split doses (at bedtime and 4  h later) may improve EDS and 
fatigue in PD, but further and larger studies are needed to prove 
its efficacy and safety considering also its depressant function 
on the respiratory centers and its abuse potential. Only one 
multicenter, open-label, polysomnographic study tested the 
efficacy of sodium oxybate after 12 weeks of therapy on 30 PD 
patients demonstrating an improvement of ESS, Pittsburgh 
Sleep Quality Inventory score, Fatigue Severity Scale score, 
and an increase in slow-wave sleep (162). Methylphenidate 
(1  mg/kg three times daily, for 3  months) was effective after 
a night of LD withdrawal and after an acute administration of 
LD, in reducing ESS in 17 patients with advanced PD (163). 
Unlike modafinil and sodium oxybate, which did not influence 
motor PD symptoms, methylphenidate improved them and, in 
particular, gait (163). Finally, caffeine (200  mg/bid) seems to 
improve motor symptoms after 3  weeks of treatment, in the 
absence of any real influence on EDS in a randomized, double-
blind, crossover, placebo-controlled, multicenter trial on 61 
patients (164).
DeeP bRaiN STiMUlaTiON (DbS)
Deep brain stimulation is an established therapy for PD. The 
effects of DBS on sleep have been proved in many studies, but it 
is not clear if DBS modifies sleep directly or indirectly improv-
ing PD symptoms. Subthalamic nucleus (STN)-DBS improves 
PSQI and PDSS scores with contrasting data on objective sleep 
parameters evaluated by polysomnography in small cohorts 
of patients (165–174). Fifteen PD patients who underwent 
STN-DBS showed an improvement in total sleep time and sleep 
efficiency with a decrease in WASO and arousal index assessed 
by VPSG. This study found no link between sleep modifications 
and motor improvement (170). Two other studies, respectively, 
in 10 and 11 patients, did not find any significant changes in 
sleep efficiency after STN-DBS, although an increase in uninter-
rupted sleep and REM sleep and a reduction in arousal index has 
been found (168, 171). Another study conducted in 10 patients 
showed also an increase in slow-wave sleep after STN-DBS, 
without any changes in sleep latency and number of awakenings 
(175, 176). DBS seems effective in reducing sleep onset insomnia 
as documented in two studies that evaluated initial insomnia 
with PDSS in 5 and 10 PD patients (167, 173). One of these 
studies, in particular, using stimulation of pedunculopontine 
nucleus demonstrated also an improvement in maintenance 
insomnia and daytime sleepiness (173). Another study showed 
an improvement in RLS symptoms in 16 patients but also an 
improvement in maintenance insomnia and EDS, after STN-
DBS (166). On the contrary, other studies did not show any 
improvement in EDS at the ESS (177–179).
The effects of STN-DBS on RBD have been evaluated in a 
study on 90 PD patients among which 47 were affected by RBD 
ascertained by clinical history assessment. After STN-DBS, RBD 
developed de novo in 16 patients within 1 year and persisted in 
other patients (180). Other studies did not report any increase 
nor improvement in RBD symptoms after DBS, but the cohorts 
examined in these studies were smaller (168, 175, 176). A study 
on 195 patients who underwent STN-DBS demonstrated the new 
onset of RLS in 11 patients (181). The same results have been 
found in 6 out of 31 PD patients after STN-DBS (182). Other 
studies have instead reported a reduction in RLS symptoms after 
surgery (166, 183).
FigURe 5 | Treatment algorithm for excessive daytime sleepiness.
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Subthalamic nucleus-DBS seems not to influence PLMs (168, 
171) nor the occurrence of apnea–hypopnea (168, 175).
CONClUSiON
Sleep disorders in PD are frequent. Understanding sleep prob-
lems in PD and their treatment is challenging, but it will help 
to improve the management of PD, improving the quality of life 
in these patients. An accurate clinical and diagnostic assessment 
is mandatory before starting the treatment. The first objective 
to achieve is to understand if SDs are a primary or secondary 
disorder and if behavioral rules or a dose modification of the 
ongoing therapy could improve SDs. Many different treatments 
options are now available to treat SDs in PD but further and larger 
randomized controlled trials are needed to confirm their efficacy 
and to solve these conflicting data. A better understanding of the 
relationship between sleep–wake regulation and PD could guide 
future research and facilitate the management of the disease.
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